Fresenius Medical Care AG banner

Fresenius Medical Care AG
XMUN:FME

Watchlist Manager
Fresenius Medical Care AG Logo
Fresenius Medical Care AG
XMUN:FME
Watchlist
Price: 39.38 EUR 0.2% Market Closed
Market Cap: €23.1B

EV/EBIT

16.8
Current
31%
Cheaper
vs 3-y median of 24.4

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
16.8
=
Enterprise Value
€29.9B
/
EBIT
€1.8B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
16.8
=
Enterprise Value
€29.9B
/
EBIT
€1.8B

Valuation Scenarios

Fresenius Medical Care AG is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (24.4), the stock would be worth €57.24 (45% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-7%
Maximum Upside
+45%
Average Upside
20%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 16.8 €39.38
0%
3-Year Average 24.4 €57.24
+45%
5-Year Average 24.4 €57.17
+45%
Industry Average 16.2 €37.94
-4%
Country Average 15.5 €36.43
-7%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
€29.9B
/
Jan 2026
€1.8B
=
16.8
Current
€29.9B
/
Dec 2026
€2.2B
=
13.8
Forward
€29.9B
/
Dec 2027
€2.4B
=
12.5
Forward
€29.9B
/
Dec 2028
€2.8B
=
10.6
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
DE
Fresenius Medical Care AG
XMUN:FME
23.1B EUR 16.8 23.6
US
CVS Health Corp
NYSE:CVS
96.8B USD 14 54.7
US
Cigna Group
XMUN:CGN
67.3B EUR 9.8 13.1
US
Cigna Corp
NYSE:CI
70.4B USD 0 11.8
DE
Fresenius SE & Co KGaA
XETRA:FRE
26.5B EUR 14.6 20.9
US
Quest Diagnostics Inc
NYSE:DGX
22B USD 16.7 22.3
US
Laboratory Corporation of America Holdings
NYSE:LH
21.7B USD 17.3 24.7
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11B EUR 10 11.4
US
Guardant Health Inc
NASDAQ:GH
11.2B USD -26.2 -26.8
US
DaVita Inc
NYSE:DVA
10.3B USD 9.8 13.8
AU
Sonic Healthcare Ltd
ASX:SHL
10.5B AUD 15.4 19.4

Market Distribution

In line with most companies in Germany
Percentile
56th
Based on 2 187 companies
56th percentile
16.8
Low
0.1 — 10.6
Typical Range
10.6 — 23.1
High
23.1 —
Distribution Statistics
Germany
Min 0.1
30th Percentile 10.6
Median 15.5
70th Percentile 23.1
Max 672.9

Fresenius Medical Care AG
Glance View

Fresenius Medical Care AG, a titan in the realm of healthcare, traces its origins back to Germany, where its journey began with an unwavering dedication to improving the lives of individuals suffering from chronic kidney failure. This imperative mission is at the core of its operations, merging compassionate patient care with cutting-edge technologies. As the leading provider of dialysis products and services globally, Fresenius Medical Care operates a vast network of renal care facilities, spanning continents, and serves a diverse patient base. The company designs and manufactures a comprehensive range of dialysis machines and related products, which are crucial to the life-sustaining process of cleansing blood when kidneys fail to function effectively. This seamless integration of service provision and product innovation underpins its success, creating a synergy that sets it apart in the healthcare sector. Revenue streams for Fresenius Medical Care are as diverse as they are robust, stemming from both its product line and its extensive network of clinics. The Clinics Division forms the backbone of its business model by offering treatment options directly to patients through a wide network of dialysis centers. Here, it garners revenue by billing healthcare providers and insurance companies for treatments administered. Meanwhile, its Products Division generates income by catering to both its proprietary clinics and third-party healthcare providers with dialysis equipment, consumables, and accompanying services. This dual-faceted structure ensures a steady flow of income, solidifying its position as an indispensable player in the global chronic kidney disease management landscape and making Fresenius Medical Care a stalwart in healthcare delivery systems worldwide.

FME Intrinsic Value
49.48 EUR
Undervaluation 20%
Intrinsic Value
Price
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett